PMID- 26896922
OWN - NLM
STAT- MEDLINE
DCOM- 20170126
LR  - 20170126
IS  - 1532-3064 (Electronic)
IS  - 0954-6111 (Linking)
VI  - 113
DP  - 2016 Apr
TI  - Adverse events among COPD patients treated with long-acting anticholinergics and 
      beta2-agonists in an outpatient respiratory clinic.
PG  - 65-73
LID - S0954-6111(16)30020-8 [pii]
LID - 10.1016/j.rmed.2016.02.002 [doi]
AB  - BACKGROUND: Chronic obstructive pulmonary disease (COPD) is the fourth leading 
      cause of death in Canada. Most patients with COPD receive long-term treatment 
      with long-acting anticholinergics (LAAC) and/or long-acting beta2-agonists (LABA). 
      Adverse events (AEs) are also likely during long-term treatment with these 
      medications. OBJECTIVE: To evaluate the prevalence of AEs in COPD patients on 
      LAAC and LABA in a real-world setting. METHODS: We conducted a cross-sectional 
      study of patients enrolled in the Registre de Donnees en Sante Pulmonaire (RESP) 
      database, which records information on Canadian patients with asthma or COPD. 
      COPD Patients completed a questionnaire about AEs that may be associated with 
      LAAC and/or LABA. The prevalence of AEs and the corresponding 95% CI were 
      calculated for three groups of patients (LAAC + LABA, LAAC alone, and LABA 
      alone). RESULTS: Most patients with COPD (n = 154) were current or ex-smokers. 
      Over 50% of patients were overweight or obese, and had an annual family income of 
      less or equal to $42,000. Dry mouth (55.2%, 40%, and 43.5%) and dry throat 
      (33.6%, 26.7%, and 34.8%) occurred most of the time or always in the LAAC + LABA, 
      LAAC, and LABA groups, respectively. Headache was reported by 17.4% of patients 
      in the LABA group, but less than 11.2% in the other groups. CONCLUSION: AEs 
      reported in this study deserve clinical attention because they may negatively 
      affect quality of life and treatment adherence of COPD patients.
CI  - Copyright (c) 2016 Elsevier Ltd. All rights reserved.
FAU - Rodrigue, Claudie
AU  - Rodrigue C
AD  - Faculty of Pharmacy, Universite de Montreal, Montreal, H3C 3J7, Canada.
FAU - Beauchesne, Marie-France
AU  - Beauchesne MF
AD  - Faculty of Pharmacy, Universite de Montreal, Montreal, H3C 3J7, Canada; Pharmacy 
      Department, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, J1H 5N4, 
      Canada; Centre de Recherche, Centre Hospitalier Universitaire de Sherbrooke, 
      Sherbrooke, J1H 5N4, Canada; Faculty of Medicine, Universite de Sherbrooke, 
      Sherbrooke, J1H 5N4, Canada.
FAU - Savaria, Francois
AU  - Savaria F
AD  - Faculty of Pharmacy, Universite de Montreal, Montreal, H3C 3J7, Canada.
FAU - Forget, Amelie
AU  - Forget A
AD  - Faculty of Pharmacy, Universite de Montreal, Montreal, H3C 3J7, Canada.
FAU - Lemiere, Catherine
AU  - Lemiere C
AD  - Faculty of Medicine, Universite de Montreal, Montreal, H3C 3J7, Canada; Research 
      Center, Hopital du Sacre-Coeur de Montreal, Montreal, H4J 1C5, Canada.
FAU - Larivee, Pierre
AU  - Larivee P
AD  - Centre de Recherche, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, 
      J1H 5N4, Canada; Faculty of Medicine, Universite de Sherbrooke, Sherbrooke, J1H 
      5N4, Canada.
FAU - Blais, Lucie
AU  - Blais L
AD  - Faculty of Pharmacy, Universite de Montreal, Montreal, H3C 3J7, Canada; Research 
      Center, Hopital du Sacre-Coeur de Montreal, Montreal, H4J 1C5, Canada. Electronic 
      address: lucie.blais@umontreal.ca.
CN  - RESP Investigators
LA  - eng
GR  - Canadian Institutes of Health Research/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160209
PL  - England
TA  - Respir Med
JT  - Respiratory medicine
JID - 8908438
RN  - 0 (Adrenergic beta-2 Receptor Agonists)
RN  - 0 (Cholinergic Antagonists)
SB  - IM
MH  - Adrenergic beta-2 Receptor Agonists/*adverse effects/therapeutic use
MH  - Aged
MH  - Aged, 80 and over
MH  - Cholinergic Antagonists/*adverse effects/therapeutic use
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Long Term Adverse Effects/etiology
MH  - Male
MH  - Middle Aged
MH  - Outpatients
MH  - Pulmonary Disease, Chronic Obstructive/*drug therapy
MH  - Quality of Life
OTO - NOTNLM
OT  - Adverse events
OT  - COPD
OT  - Long-acting bronchodilators
OT  - Obstructive lung disease
FIR - Bacon, Simon
IR  - Bacon S
FIR - Beauchesne, Marie-France
IR  - Beauchesne MF
FIR - Blais, Lucie
IR  - Blais L
FIR - Lavoie, Kim
IR  - Lavoie K
FIR - Lemiere, Catherine
IR  - Lemiere C
FIR - Moullec, Gregory
IR  - Moullec G
FIR - Pepin, Veronique
IR  - Pepin V
FIR - Spahija, Adriana
IR  - Spahija A
EDAT- 2016/02/22 06:00
MHDA- 2017/01/27 06:00
CRDT- 2016/02/22 06:00
PHST- 2015/10/16 00:00 [received]
PHST- 2016/01/28 00:00 [revised]
PHST- 2016/02/06 00:00 [accepted]
PHST- 2016/02/22 06:00 [entrez]
PHST- 2016/02/22 06:00 [pubmed]
PHST- 2017/01/27 06:00 [medline]
AID - S0954-6111(16)30020-8 [pii]
AID - 10.1016/j.rmed.2016.02.002 [doi]
PST - ppublish
SO  - Respir Med. 2016 Apr;113:65-73. doi: 10.1016/j.rmed.2016.02.002. Epub 2016 Feb 9.